🔘 On The Lancet - Assessing the efficacy and safety of adjuvant nivolumab + ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914) #immunotherapy #kidneycancer thelancet.com/journals/lance…

Checkmate-914 (adjuvant nivo/ipi) vs placebo in high-risk Kidney Cancer is out in the The Lancet: the study is negative with no DFS/OS advantage. 33% disc. for toxicity could be the main culprit. Thank you for all the patients/families who believe in thelancet.com/journals/lance…

Current Issue: Progression-free Survival After Second Line of Therapy for Metastatic ccRCC in Patients Treated with First-line Immunotherapy Combinations buff.ly/3Uf2NoX Chung-Han Lee 李宗翰, MD/PhD Ritesh Kotecha David H Aggen, MD PhD Neil Shah Dr. Darren Feldman Robert Motzer MD #MedTwitter #UroSoMe

1/ Excited to announce updates from the #CLEAR trial in The Lancet Oncology: A long-term follow-up of lenvatinib + pembrolizumab vs sunitinib in this brief tweetorial: And yet another win for patients with renal cell carcinoma #RCC sciencedirect.com/science/articl… OncoAlert ASCO ESMO - Eur. Oncology

With Yuji Miura in the renal cancer session in 🇯🇵 . PD-1/VEGF combos ⬆️ RR in papillary RCC. Dr Juninho Inokuchi thinks they should be a standard of care as single agent TKI not good enough. Thr SAMETA trial of MET inhibition & durvalumab in MET +ve is important #JSMO2023

Dr. Martin Voss from Memorial Sloan Kettering Cancer Center, 2021 KCCure #chromophobe research grant recipient, updated pts on the potential of IL-15 as tx for this rare subtype of #kidneycancer. Fingers crossed that this will lead to the first ever chRCC specific clinical trial!

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations buff.ly/42KOq0o Chung-Han Lee 李宗翰, MD/PhD Ritesh Kotecha David H Aggen, MD PhD Neil Shah Dr. Darren Feldman Robert Motzer MD

Huge congrats to Toni Choueiri, MD & team for paving the way towards a new regimen for #kidneycancer in this The Lancet Oncology paper! Neeraj Agarwal, MD, FASCO Petros Grivas Rana McKay, MD, FASCO KCCure KidneyCAN Kidney Cancer

Tom Powles Toni Choueiri, MD Brian Rini, MD Robert Motzer MD And your missing the best, the 4 year OS eat al. From the CLEAR trial that I am presenting. Stay tuned.

The deadline is extended! KidneyCAN OncoAlert #KCRS23

1/ Results from #COSMIC-313 are out NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by Charles Swanton Andres Cervantes #ESMO22 Thread 🧵==> nejm.org/doi/full/10.10…

Congrats to Robert Motzer MD and team on their recent study in NEJM! Phase 3 results showed progression-free survival for people with #kidneycancer was significantly longer with cabozantinib plus nivolumab and ipilimumab than with nivolumab and ipilimumab alone. nejm.org/doi/full/10.10…

RR continue to climb in Chung-Han Lee 李宗翰, MD/PhD Robert Motzer MD Memorial Sloan Kettering Cancer Center trial of cabo/nivo in nccRCC. Need to establish role of TKI/IO in nccRCC - best way to do this is to support trials like SWOG Cancer Research Network 2200 & #STELLAR304. @uromigos Brian Rini, MD Tom Powles ASCO #ASCO23

Ab#4518 #ASCO23 ASCO Kidney Cancer Phase 2 results of lenvatinib + pembrolizumab in pts with non-clear cell #kidneycancer 49% ORR in a 158 pt cohort of papillary, unclassified, chromophobe, translocation RCC. Laurence Albiges meetings.asco.org/abstracts-pres…

Dr. Robert Motzer MD with an important presentation of #CHECKMATE914 Part A subgroup analyses. ASCO #ASCO23 While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit

A smaller difference by the number of cycles received, likely not accounting for the absence of an effect in the overall trial! ASCO #ASCO23

Masterful presentation by Robert Motzer MD reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 OncoAlert

Humbled and thrilled to receive the Burroughs Wellcome Fund CAMS. I am excited to meet these incredible awardees. Thanks to all my mentors for their unwavering support. A big shout out to Charles Sawyers for his mentorship in the maturation of my career as a physician–scientist Memorial Sloan Kettering Cancer Center

The phase 3 CheckMate 914 trial revealed that nivolumab did not achieve the primary goal of improving disease-free survival vs placebo in patients with localized #RCC who were at an increased risk of relapse after nephrectomy. #KCSM | Robert Motzer MD targetedonc.com/view/adjuvant-…

The Renee Maria Saliby #kidneycancer biomarker paper in Cancer Cell is online with a detailed tweetorial: consistent benefit across all subgroups of IO-based therapies over VEGF TKI OncoAlert Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber Yale Cancer Center #WCRM #DANA9 #Teamwork with amazing collaborators